Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Accounts Payables: 2019-2024

  • Burning Rock Biotech's Accounts Payables rose 81.72% to $4.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.6 million, marking a year-over-year increase of 81.72%. This contributed to the annual value of $4.6 million for FY2024, which is 81.72% up from last year.
  • Latest data reveals that Burning Rock Biotech reported Accounts Payables of $4.6 million as of Q4 2024, which was up 81.72% from $2.5 million recorded in Q4 2023.
  • Burning Rock Biotech's Accounts Payables' 5-year high stood at $9.9 million during Q4 2021, with a 5-year trough of $2.5 million in Q4 2023.
  • Over the past 3 years, Burning Rock Biotech's median Accounts Payables value was $4.6 million (recorded in 2024), while the average stood at $4.9 million.
  • In the last 5 years, Burning Rock Biotech's Accounts Payables spiked by 210.40% in 2020 and then slumped by 65.56% in 2023.
  • Over the past 5 years, Burning Rock Biotech's Accounts Payables (Quarterly) stood at $5.4 million in 2020, then spiked by 82.03% to $9.9 million in 2021, then declined by 25.38% to $7.4 million in 2022, then tumbled by 65.56% to $2.5 million in 2023, then skyrocketed by 81.72% to $4.6 million in 2024.
  • Its last three reported values are $4.6 million in Q4 2024, $2.5 million for Q4 2023, and $7.4 million during Q4 2022.